We investigated the hypolipidemic and antioxidative effects on male ICR mice of a glycoprotein isolated from Rhus verniciflua Stokes (RVS) fruit. The administration of the RVS glycoprotein (100 mg/kg) for two weeks resulted in a significant decrease in such plasma lipid levels as total cholesterol (TC), triglyceride (TG), and low-density lipoprotein (LDL). The levels of TC, TG and LDL in the hyperlipidemic model were significantly increased, whereas the high-density lipoprotein (HDL) level was considerably decreased. The 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase activity and the level of thiobarbituric acid-reactive substances (TBARS) were significantly elevated, whereas the production of nitric oxide (NO) was diminished. Moreover, the administration of the RVS glycoprotein prior to inducing hyperlipidemic mice suppressed the increase in the plasma lipid levels (TC, TG and LDL), and decrease in the HDL level in Triton WR-1339-induced hyperlipidemic mice. Furthermore, the RVS glycoprotein significantly inhibited the activity of HMG-CoA reductase and the levels of TBARS in the hyperlipidemic mice. In addition, the activities of detoxicant enzymes [catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx)] were gradually augmented after a supplement with the RVS glycoprotein. The results suggest that the RVS glycoprotein would be effective in preventing an increase in the plasma lipid levels and in improving the antioxidant levels. This protein might be useful as a therapeutic agent.
the development of coronary artery disease and the progression of atherosclerotic lesions. 1) Normally, most cholesterol serves as a structural element in the cell membranes, whereas much of the rest is in transit through the blood or functions as the starting material for the synthesis of bile acids in the liver, steroid hormones in endocrine cells, or vitamin D in the skin. However, high levels of cholesterol, particularly lowdensity lipoprotein (LDL), accumulate in the extracellular subendothelial space of arteries and are modified to form oxidized LDL, which is highly atherogenic and toxic to vascular cells. 2, 3) This can cause a variety of serious diseases such as atherosclerosis, hypertension, obesity, diabetes, functional depression of some organs, etc. Once lipids undergo peroxidative change in the arterial wall, the eventual result is tissue injury. An increase in reactive oxidants during hypercholesterolemia can cause the abnormal function of endothelial cells via reduced nitric oxide (NO) availability. 1, 4) In addition, there are changes in the enzymatic as well as nonenzymatic antioxidative defense systems such as superoxide dismutase (SOD), catatalase (CAT), glutathione peroxidase (GPx), ascorbic acid, -tocopherol, and glutathione during hyperlipidemia, suggesting a reduced resistance to reactive oxidant-mediated damage. 5) Thus, there is a relationship between hypercholesterolemia, the increased production of oxygen free radicals, 3) and endothelial-derived NO. 4) There is also a relationship between an increase in the production of oxygen free radicals and the antioxidative defense system. 6, 7) This defense system represents the essential defense against the potential toxicity of reactive oxidants generated by severe oxidative conditions such as chronic inflammation and abnormal metabolism. Therefore, some naturally occurring compounds/drugs with antioxidative potential may have beneficial effects on the overall disease processes. [8] [9] [10] y To whom correspondence should be addressed. Tel: +82-62-530-2115; Fax: +82-62-530-2129; E-mail: ktlim@chonnam.ac.kr or kyetaeklim@ hotmail.com Abbreviations: RVS, Rhus verniciflua Stokes; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TBARS, thiobarbituric acid-reactive substances; NO, nitric oxide; HMG-CoA reductase, 3-hydroxy-3-methylglutaryl CoA reductase; CAT, catalase; SOD, superoxide dismutase; GPx, glutathione peroxidase Rhus verniciflua Stokes (RVS) has traditionally been used as a food additive and herbal medicine in South Korea for a long time. 11) Several studies have shown that RVS glycoprotein has cytoprotective ability against reactive free radicals, especially hydroxyl radical-induced cytotoxic injury, by enhancing the detoxicant enzymes in cultured mouse hepatocytes. 12) We have recently isolated a glycoprotein from RVS fruit (RVS glycoprotein) and found it to have an approximate molecular mass of 36 kDa and to be made up of carbohydrate (38.75%) and protein (61.25%). In a previous study, our results showed that the RVS glycoprotein had strong antioxidative abilities and modulatory effects on the transcriptional factor levels of nuclear factor-B (NF-B) and activator protein-1 (AP-1). 13) However, there is no evidence of its biological effect on hypercholesterolemic animal models.
We examined in this present study the effect of the RVS glycoprotein on the plasma levels of lipids, including TC, TG, LDL and HDL, in normal mice or experimentally induced hyperlipidemic mice. We also evaluated the level of TBARS, nitric oxide production, and HMG-CoA reductase activity, and the activities of detoxicating enzymes such as CAT, SOD and GPx.
Materials and Methods
Chemicals. All the plastic materials were purchased from Falcon Labware (Becton-Dickinson, Franklin Lakes, NJ, USA). Cholestyramine, dextran sulfate, -nicotinamide adenine dinucleotide phosphate (-NADPH), and triton WR-1339 were obtained from Sigma (St. Louis, MO, USA). The other chemicals and reagents were of the highest quality available.
Preparation of the RVS glycoprotein. The fruit of Rhus verniciflua Stokes was collected from the traditional market of Naju in the Chonnam province of South Korea, and RVS glycoprotein was isolated from it as described previously. 13) Briefly, each fruit was broken into small pieces and soaked in ethanol for several months in a dark basement. The ethanol extract was passed through Whatman filter paper (No. 2) and concentrated with a rotary evaporator (Buchi, Switzerland). The concentrated solution was dried with a freezedryer (Sam Won, Seoul, Korea). Five grams of the dried crude ethanol extract was dissolved in distilled water and applied to a silica gel column (4 Â 28 cm, 28-200 mesh, 22 A). Ordered elution was performed with distilled water, 70% ethanol, absolute ethanol, and 5% acetic acid. Only the 70% ethanol-eluted solution was collected, because it had demonstrated a biological function in trials before the experiment. The dried powder was dissolved again with distilled water. The solution was precipitated with 80% ammonium sulfate and dialyzed overnight with a Spectra/por dialysis membrane (MWCO 6,000-8,000, CA, USA) against 20 mM Tris-HCl (pH 7.4). After this dialysis, the contained solution was dried with a freeze dryer and stored at À70 C. After SDS-polyacrylamide gel electrophoresis on 18% separation gel, the RVS glycoprotein was eluted with a Mini Whole Gel Eluter (Bio-Rad, CA, USA). The purity of RVS glycoprotein is more than 95%. The dried sample 30.5 mg (0.61% from the original sample) was stored at À20 C during the experimental period. We used in this study the RVS glycoprotein with a molecular weight of 36 kDa.
Animals and diets. Male mice (ICR), aged 5 weeks, were purchased from Daehan Lab. (Animal Research Center Co., Dae Jeon, Korea) and housed according to the animal-care guidelines approved by the animal-care committee of the American Society of Mammalogists 14) in the experimental animal room of the Veterinary College of Chonnam National University (CNU). The mice were fed on a commercial diet and water ad libitum throughout the experimental period, and kept for at least 1 week prior to each experiment.
To investigate the hypolipidemic effect of the RVS glycoprotein, the mice were divided into three groups of six mice per group (the control and two RVS glycoprotein treatment groups). The RVS glycoprotein was administered orally at a dose of 50 or 100 mg/body weight (kg) once a day for 2 weeks, and the control group was administered with 100 ml of phosphatebuffered saline (PBS). During day 15, blood was collected by cardiac puncture with a syringe and centrifuged at 1;500 Â g for 20 min at 4 C, the supernatant was separated and stored at À70 C for the cholesterol assay.
The base of the experimentally induced hyperlipidemic animal model was the Triton WR-1339-induced model according to the method of Lee et al. 15) and Kusama et al.
16) The mice were divided into four groups of six mice per group (the control, Triton WR-1339 and two RVS glycoprotein treatment groups). RVS glycoprotein was administered orally once a day for 3 days. Triton WR-1339 was dissolved in PBS to a final concentration of 10%, and intraperitonially injected at a dose of 400 mg/body weight (kg). 18 h after the Triton WR-1339 injection, 1-ml blood samples were drawn from the mice by cardiac puncture under diethyl ether anesthesia.
Determination of the plasma lipoprotein levels. The amounts of plasma lipoprotein were measured according to the method of Warnick et al., 17) and all experiments for fractionation and determination of the various lipoproteins in the plasma were conducted as previously described.
15) The separation of the cholesterol fractions from total cholesterol is depicted as follows: To evaluate the amount of total cholesterol (TC), we separately determined VLDL, LDL and HDL. The fractions containing VLDL and LDL were determined by mixing 1 ml of plasma containing EDTA with 100 ml of reagent A [equal volumes of dextran sulfate (MW 50;000 AE 5;000; 20 g/l) and MgCl 2 (1.0 M)], standing for 10 min, and by centrifuging at 10;000 Â g for 2 min. We used half of the supernatant for VLDL and LDL, and the rest for HDL. To assess the fraction containing HDL, 0.5 ml of the supernatant was further mixed with 50 ml of reagent B [1 volume of dextran sulfate (40 g/l) with 3 volumes of MgCl 2 (2.0 M)] for 15 min, before being centrifuged at 100;000 Â g for 15 min. The resulting supernatant was designated as the fraction containing HDL.
The amounts of each fraction (those containing VLDL, LDL and HDL) were quantified by the colorimetric method described previously. 18) Briefly, one milliliter of reagent C [1:100 (v/v) of an FeCl 3 solution (1 g of FeCl 3 in 10 ml of glacial acetic acid) and 18 M H 2 SO 4 ] was added carefully to tubes containing 100 ml of each fraction. After standing for 1 h at 4 C, each sample was measured at 560 nm, and the concentration quantified using a standard curve for cholesterol according to the following formula. 20) from the livers of mice. The mice had been fed on diet containing 5% cholestyramine for 2 days and then switched to a diet containing 5% cholestyramine plus RVS glycoprotein [50 and 100 mg/body weight (kg)] for 2 days. Each mouse liver was homogenized at 4 C in 25 ml of buffer A (0.1 M sucrose, 0.04 M KH 2 PO 4 and 0.03 M potassium EDTA; pH 7.2) with a PotterElvejheim homogenizer (Bräun, Melsungen, Germany) at a moderate speed. To obtain the microsomes, the cell debris and mitochondria were removed by centrifugation, and the resulting supernatant was re-centrifuged at 100;000 Â g for 1 h. After suspending the pellet in the same buffer, the pellet was obtained from further centrifugation (100;000 Â g for 45 min) and resuspended in 3 ml of buffer A, before the suspension was added to an equal volume of 50% glycerol in buffer B (buffer A plus 10 mM DTT). The final suspension was incubated, diluted three-fold with buffer B to give 8.3% glycerol and centrifuged at 100;000 Â g for 1 h. The resulting supernatant was used to determine the HMG-CoA reductase activity. TBARS assay. Lipid peroxidation was estimated according to the presence of TBARS in plasma using the method of Buege and Aust. 21) One volume of a sample was thoroughly mixed with two volumes of a stock solution containing 15% w/v trichloroacetic acid, 0.375% w/v thiobarbituric acid and 0.25 N HCl. The mixture was heated for 30 min in a boiling water bath. After cooling, the flocculatd precipitate was removed by centrifugation at 1;000 Â g for 10 min, and the absorbance of the sample was measured at 535 nm. 1,1,1,3-Tetraethoxypropane was used as the standard. Each data value is expressed as a percentage of the control.
Plasma NO levels. The production of NO by the endothelium was indirectly assessed by measuring the nitrite levels in the plasma by a calorimetric method based on the Griess reaction. 22) A plasma sample was diluted four times with distilled water and deproteinized by adding 1/20 volume of zinc sulfate (300 g/l) to a final concentration of 15 g/l. After centrifugation at 10;000 Â g for 5 min, the supernatant (100 ml) was mixed with 100 ml of the Griess reagent (1% sulfanilamide and 0.1% N-1-naphthylethylenediamine dihydrochloride in 2.5% polyphosphoric acid). After 10 min at room temperature, the absorbance was measured at 540 nm with a MicroReader (Hyperion, USA). Nitrite was quantified against a standard curve for sodium nitrate.
Measurement of the detoxicating enzyme activities. ICR mice were administered with Triton WR-1339 in the presence or absence of RVS glycoprotein. The liver homogenized with 5 ml of a 0.25 M sucrose buffer (pH 7.5) containing 10 mM EDTA. The nuclear fraction was removed by centrifugation (600 Â g for 10 min at 4 C), and the supernatant was re-centrifuged at 10;000 Â g for 20 min to collect the mitochondrial fraction (pellet) for a CAT assay. The supernatant was ultra-centrifuged at 100;000 Â g for 1 h at 4 C to isolate the cytosolic fraction for the SOD and GPx assays. The resulting supernatant was used for evaluating the activities of detoxicating enzymes as described next, and the amount of protein was measured by the Lowry method.
23) The proteins were stored at À70 C for further experimental use.
The SOD activity was measured according to the method of Beauchamp and Fridovich. 24) An adequate amount of the liver supernatant was mixed with a reaction mixture (3 ml) which contained 0.1 mM EDTA, 25 mM NBT, 0.1 mM xanthine, and a 50 mM sodium carbonate buffer (pH 10.2). The reaction was initiated by adding 2 mU/ml of xanthine oxidase and maintained under two 40 W lamps at 25 C. After 15 min, the inhibition rate of NBT reduction was spectrophotometrically determined at 560 nm. One unit of SOD is defined as the amount of enzyme required to reduce NBT by 50%. The specific activity of SOD is expressed as unit/ mg of protein in each supernatant, the value being calculated as a percentage of the control value.
The CAT activity was measured according to the method of Thomson et al. 25) The liver supernatant was mixed with 2.8 ml of a 50 mM phosphate buffer (pH 7.4). After equilibration at 30 C for 5 min, the reaction was started by adding 0.2 ml of 100 mM sodium perborate (pH 7.4). The catalase activity, which reduced sodium perborate as a substrate, was spectrophotometrically assessed by monitoring at 220 nm the consumption of hydrogen peroxide for 2 min. One unit of catalase activity is defined as the amount of enzyme required to reduce 1 mM H 2 O 2 /min. The results are expressed as unit/mg of protein for supernatant, the values being calculated as a percentage of the control value.
The GPx activity was measured according to the method of Paglia and Valentine.
26) The liver supernatant was added to a reaction mixture consisting of 1 mM EDTA, 1 unit of glutathione reductase, 1 mM glutathione, 0.25 mM H 2 O 2 and 1 mM NaN 3 in 50 mM phosphate buffer (pH 7.0). The reaction was initiated by adding NADPH to give a final concentration of 0.2 mM. One unit of GPx activity is defined as the amount required to oxidize 1 mM NADPH/min. Each result is expressed as unit/mg of protein in each supernatant, the value being calculated as a percentage of the control value. 
Results

Effect of RVS glycoprotein on the plasma cholesterol levels
To investigate the effect of the RVS glycoprotein on the lipid levels in mouse plasma, the amounts of TC, TG, HDL and LDL were measured. There was no significant difference in the relative weight gain or liver weight between the treatment groups (data not shown). As shown in Fig. 1 , the amounts of TC, TG and LDL were significantly decreased in a dose-dependent manner after the addition of the RVS glycoprotein in comparison with the control. For instance, the levels of TC, TG and LDL were respectively reduced by 15.2%, 25.6% and 21.6% in the mice fed with 100 mg/kg of RVS glycoprotein, compared with the control. However, the level of HDL showed no significant change in this group. Furthermore, when the mice were treated with Triton WR-1339 in the absence of the RVS glycoprotein, the amounts of TC, TG and LDL after Triton WR-1339 injection were respectively increased by 95.1%, 228.9%, and 86.9%, compared with the control, whereas the level of HDL was reduced by 21%, compared with the control (Fig. 2) . However, pretreatment with the RVS glycoprotein (50 or 100 mg/kg) prior to the Triton WR-1339 injection significantly reduced the levels of TC, TG and LDL in a dose-dependent manner. For instance, when the mice had been pretreated with 100 mg/kg of the RVS glycoprotein, the amounts of TC, TG and LDL were gradually diminished by 29.9%, 49.3% and 26.7%, respectively, compared with the Triton WR-1339 treatment group. The level of HDL in the mice pretreated with the RVS glycoprotein (100 mg/ kg) was markedly increased by 18.7%, compared with the Triton WR-1339-treated group.
Effect of RVS glycoprotein on hepatic HMG-CoA reductase activities
The effect of the RVS glycoprotein on the activity of hepatic HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, was evaluated in hypercholesterolemic mice. As shown in Fig. 3 , the relative activity of HMG-CoA reductase in the cholestyraminefed group was increased by 47.9%, compared with the control. In contrast, the activities of HMG-CoA reductase were gradually reduced by 21.5% and 39.3% upon supplementation with the RVS glycoprotein (50 and 100 mg/kg) in the presence of cholestyramine, compared with the cholestyramine alone group. Because Triton WR-1339 causes a marked increase in hepatic cholesterol synthesis, the effect of the RVS glycoprotein on the activity of HMG-CoA reductase was also examined in the Triton WR-1339-induced hyperlipidemic mice. As expected, after the Triton WR-1339 injection, the activity of HMG-CoA reductase was increased by 33.5%, compared with the control. However, pretreatment with RVS glycoprotein (50 or 100 mg/kg) prior to the Triton WR-1339 injection resulted in a gradual decrease in the activity of HMG-CoA reductase by 14.6% and 21.5%, compared with the treatment by Triton WR-1339 alone.
Inhibitory effect of RVS glycoprotein on lipid peroxidation
The effect of the RVS glycoprotein on lipid peroxidation in the Triton WR-1339-induced hyperlipidemic mice is presented in Fig. 4. The results show the level of TBARS as a marker of the plasma lipid peroxidation, and are expressed as relative percentages. When the mice were treated with the RVS glycoprotein at a dose of 100 mg/kg of body weight/day for 2 weeks, the TBARS level was reduced by 7.3%, compared with the control. Furthermore, the TBARS level in the Triton WR-1339-treated mice was increased by 24.5%, compared with the control group. However, the administration of the RVS glycoprotein prior to the Triton WR-1339 injection resulted in a gradual decrease of TBARS level by 9.4% and 13.5% according to dose, compared with the Triton WR-1339 treatment group.
Inhibitory effect of RVS glycoprotein on the plasma nitric oxide (NO) production
The effect of RVS glycoprotein on the level of plasma NO in the hyperlipidemic mice was evaluated and is presented in Fig. 5 . When the mice were treated with Triton WR-1339 in the absence of the RVS glycoprotein, the level of plasma nitric oxide in the Triton WR-1339-treated mice was decreased by 19.2%, compared with the control. However, the level of plasma nitric oxide was gradually increased after the addition of the RVS glycoprotein (50 or 100 mg/kg) in the presence of Triton WR-1339, although the level of plasma NO in the presence of the RVS glycoprotein was not changed significantly without Triton WR-1339. The RVS glycoprotein was orally administered at doses of 50 and 100 mg/body weight (kg) once a day for 2 weeks and the control group was administered with 100 ml of phosphate-buffered saline (PBS). The amount of plasma cholesterol was measured as described in the Materials and Methods section. Six mice were used in a group, and the analysis was carried out in triplicate.
Ã p < 0:05 and ÃÃ p < 0:01, as compared with the control. C: control The RVS glycoprotein was orally administered 1 h before the Triton WR-1339 injection once a day for 3 days. The amount of plasma cholesterol was measured as described in the Materials and Methods section. Six mice were used in a group, and the analysis was carried out in triplicate.
# p < 0:01, as compared with the control. Ã p < 0:05 and ÃÃ p < 0:01, as compared with the Triton WR-1339 treatment group. C: control 
Effect of RVS glycoprotein on the detoxicating enzyme activities
To investigate whether the antioxidative activities of the RVS glycoprotein would be mediated by an increase in the detoxicating enzymes, SOD, CAT and GPx, the activities in a liver extract from the hyperlipidemic mice were examined after an administration of the RVS glycoprotein. As shown in Fig. 6 , when the mice were treated with the RVS glycoprotein alone, the activities of the hepatic detoxicating enzymes, CAT and GPx, were significantly higher than that the control group, although the activity of SOD was not changed. For instance, the activities of CAT and GPx in the presence of the RVS glycoprotein were increased by 12.8% and 49%, compared with the control. Furthermore, the activities of the detoxicating enzymes were decreased in the Triton WR-1339-induced hyperlipidemic mice. The reduced activities of the detoxicating enzymes, however, were all increased in a dose-dependent manner after the addition of the RVS glycoprotein. For instance, when the mice were pretreated with 100 mg/kg of the RVS glycoprotein prior to the Triton WR-1339 injection, the activities of SOD, CAT and GPx were respectively increased by 7.3%, 12.5% and 34.4%, compared with the Triton WR-1339-treated group.
Discussion
Atherosclerosis is connected with increased levels of cholesterol, especially LDL, as well as with triglycerides. Since LDL constitutes the main cholesterol carrier in the plasma, it influences the plasma cholesterol levels and is closely related to the etiology of atherosclerosis. It has been postulated that LDL may accumulate within the arterial walls and, thus, narrow the arteries. Oxygenderived radicals attack LDL, and this oxidatively modified LDL cannot only damage arterial tissue, but can also attack white blood cells. It consequently initiates and promotes atherosclerosis.
2) Fig. 4 . Inhibitory Effect of the RVS Glycoprotein on Lipid Peroxidation. Lipid peroxidation was estimated by the TBARS value, as described in the Materials and Methods section. Six mice were used in a group, and the analysis was carried out in triplicate.
# p < 0:01, as compared with the control.
Ã p < 0:05 and ÃÃ p < 0:01, as compared with the Triton WR-1339 treatment group. C: control
Fig. 5. Inhibitory Effect of the RVS Glycoprotein on Plasma Nitric
Oxide (NO) Production. The production of NO was indirectly assessed by measuring the nitrite level in the plasma, as described in the Materials and Methods section. Six mice were used in a group, and the analysis was carried out in triplicate.
# p < 0:01, as compared with the control. Ã p < 0:05 and ÃÃ p < 0:01, as compared with the Triton WR-1339 treatment group. C: control Fig. 6 . Effects of the RVS Glycoprotein on Detoxicating Enzyme
Activities.
The specific activities of antioxidative enzyme in the liver of mice were measured by SOD, CAT and GPx assays, as described in the Materials and Methods section. Six mice were used in a group, and the analysis was carried out in triplicate.
Ã p < 0:05 and ÃÃ p < 0:01, as compared with the Triton WR-1339 treatment group. C: control There is increasing evidence to support the protective effects of antioxidants under a variety of pathological conditions such as cardiovascular disease. 3, 8) Furthermore, various clinical studies have suggested that lowering the blood cholesterol level has a significant effect on preventing and inhibiting the progression of atherosclerosis. 8, 9) Many polysaccharide-protein complexes (glycoproteins) have been isolated from mushrooms, fungi, yeasts, algae, lichens, and plants and the biological activities of these glycoproteins have been evaluated in terms of their clinical efficacy, such as their immunomodulatory, antioxidative, hypolipidemic and hypocholesterolemic effects, although the mechanisms for the biological functions of glycoproteins are still not completely understood. 9, 27) We have recently found a glycoprotein with an approximate molecular mass of 150 kDa which had been isolated from Solanum nigrum Linne (SNL). This glycoprotein had a strong scavenging effect against reactive oxygen radicals, and anti-proliferation activity against human cancer cells. 28) More recently, we have investigated its hypocholesterolemic and hypolipidemic effect on experimentally induced mice by inhibiting the HMG-CoA reductase activities and consequent detoxicating enzymes activities in the mouse liver. 15) Furthermore, an extract from Ficus Carica Linnaeus (FCL), which is used for oriental medical purposes such as nourishment, haemorrhoid treatment and as a helminthic agent, also had a biological function in changing the cholesterol levels in the plasma. 29) We therefore expected a supplement of the RVS glycoprotein to reduce the oxidation of LDL and to influence cholesterol levels in mice plasma, because of its reported antioxidative properties.
13) The results of a treatment with the RVS glycoprotein showed a significantly effect on the plasma lipid levels by reducing plasma TC, and TG and LDL, indicating its function as a potential hypolipidemic agent (Fig. 1) . Furthermore, the inhibitory effects of the RVS glycoprotein on plasmic lipid levels were also revealed in the hyperlipidemic model that was induced by Triton WR-1339. Triton WR-1339 is one of the many well known non-ionic detergents that induce the elevation of plasma cholesterol and triglyceride levels by increasing the hepatic cholesterol biosynthesis. 30) In addition, it has been shown that Triton WR-1339 increased the HMG-CoA reductase activity in the liver.
31) The Triton WR-1339 model has therefore been examined not only as a screening method for hypolipidemic agents, but also as a means for elucidating lipid metabolism. 15, 30, 32) The plasma lipid levels (TC, TG and LDL) were increased after a treatment with Triton WR-1339, as similarly conducted in previous studies. 33, 34) It should be noted that when we administered Triton WR-1339, the lipid levels (total cholesterol, triglyceride, and LDL) in the mice plasma increased, compared with the control. The increased lipid levels in the mice plasma were expressed with hyperlipidemic mice in this study. The RVS glycoprotein significantly decreased the levels of TC, TG and LDL in the Triton WR-1339-induced hyperlipidemic mice in a dose-dependent manner (Fig. 2 ). More specifically, the level of HDL was significantly increased after the addition of the RVS glycoprotein in the presence of Triton WR-1339. The level of HDL is generally inversely correlated with the risk of cardiovascular disease in both human and laboratory animal studies, and increased HDL decreases the development of atherosclerosis. 35) Thus, an increase in the HDL level by supplementation with the RVS glycoprotein may be responsible, in part, for the anti-atherosclerotic effect in mice.
Since a great part of the cholesterol in the body is synthesized de novo, mostly in the liver, the search for drugs to inhibit cholesterol biosynthesis has long been pursued as a means to lower the levels of plasma cholesterol. As high levels of cholesterol are correlated with an increased occurrence of atherosclerosis, 2) the therapy for hypercholesterolemia is focused mainly on inhibition of the selective cholesterol biosynthesis pathway in the liver. The enzyme, HMG-CoA reductase, catalyzes the rate-limiting reaction on the mevalonate pathway 36) and acts early on this biosynthetic pathway. Inhibitors of cholesterol biosynthesis, for instance, particularly those that inhibit HMG-CoA reductase, are widely used to lower the cholesterol levels. The effectiveness of HMG-CoA reductase inhibitors to decrease plasma cholesterol levels in animals and humans is well documented. 37) Cholestyramine increases the production of bile acid from the ileum and inhibits its passive absorption in the colon, resulting in the stimulation of HMG-CoA reductase activity. 38) In this present study, supplementation with the RVS glycoprotein significantly inhibited the HMG-CoA reductase enzyme activities toward cholesterol biosynthesis in cholestyramine-fed mice (Fig. 3) . Our results also show that the HMG-CoA reductase activity was increased in Triton WR-1339-induced hyperlipidemic mice, which is in agreement with reports of other studies made. 31) However, such increased activities of hepatic HMGCoA reductase were decreased after administration of the RVS glycoprotein in both the cholestyramine-and Triton WR-1339-treated mice in a dose-dependent manner. Based on these results, it is proposed that RVS glycoprotein administration involved suppression of endogenous cholesterol biosynthesis by inhibiting the activities of hepatic HMG-CoA reductase. The possibility exists that the RVS glycoprotein might have upregulated the hepatic LDL receptor, thus increasing the cholesterol clearance, in which case the mechanism still remains to be elucidated through further studies. It is possible, that in addition to upregulation of the hepatic LDL receptor, the suppression of endogenous cholesterol biosynthesis by the RVS glycoprotein limited the availability of cholesterol to the liver for VLDL production.
On the other hand, the administration of the RVS glycoprotein suppressed the increased TBARS level in hyperlipidemic mice. As hypercholesterolemia leads to the increased production of oxygen free radicals, 3) it exerts its cytotoxic effect by causing lipid peroxidation, resulting in the formation of malondialdehyde (MDA). Determining lipid peroxidation via the TBARS level provides an indirect measurement of antioxidative deficit. A decrease in lipid peroxidation leads to a reduction in the arterial wall cholesterol content. Thus, the reduction of lipid peroxidation is associated with a decrease in the atherosclerosis caused by hyperlipidemia. It seems from the results that the RVS glycoprotein had an antioxidative effect and counteractive effect against hyperlipidemia to some extent. Therefore, our results demonstrate that, in addition to lowering cholesterol, the RVS glycoprotein also helped in inhibiting lipid peroxidation and the oxidation of lipoproteins in hyperlipidemic mice (Fig. 4) .
The plasma NO concentration was decreased in the hyperlipidemic model. Endothelial-derived NO exerts vasodilatory, growth regulatory, and anti-inflammatory effects, thus being an important regulator of cardiovascular homeostasis. However, oxidatively modified LDL activates endothelial cells, leading to an alteration of the functional and structural integrity of the endothelial barrier, thus resulting in endothelial dysfunction, namely the production of oxidative stress during LDL oxidation, the inactivation of NO, and the inhibition of NO synthesis by nitric oxide synthase (NOS).
4) The reduced level of NO production in the hyperlipidemic mice was gradually increased by pretreatment with the RVS glycoprotein (Fig. 5 ). This may have been due to enhancing the detoxicating enzymes by supplementing the RVS glycoprotein in the liver and/or its antioxidative effect. Indeed, treatment with the RVS glycoprotein resulted in an increase in the activities of CAT and GPx, although it did not result in a significant change in the activity of SOD. SOD plays an important role in protecting cells from oxidative damage by converting superoxide radicals into hydrogen peroxide. The resulting hydrogen peroxide is further metabolized by CAT and GPx, where by CAT detoxifies hydrogen peroxide and GPx catalyses the destruction of hydrogen peroxide and lipid peroxide. Several studies have shown that hyperlipidemia reduces the antioxidative defense system, 6, 7) thereby elevating the lipid peroxide content, resulting in the production of toxic intermediates. 3, 5) Many researchers have therefore tried to obtain bioactive substances which have a cytoprotective ability against cellular oxidative damage, as well as an enhancing ability of antioxidative enzyme activities. 3, 8) A supplement of the RVS glycoprotein, in this present study, increased the activities of detoxicating enzyme in the hyperlipidemic mice. Interestingly, the RVS glycoprotein tended to elevate the activities of CAT and GPx without affecting the SOD activity (Fig. 6) . Therefore, the increased enzyme activities resulting from the treatment with the RVS glycoprotein may prevent oxidative damage by detoxifying reactive oxygen species and inhibiting lipid peroxidation thus reducing hyperlipidemia.
In conclusion, the results show that the RVS glycoprotein had the ability to enhance the HDL level, to lower plasma lipids (TC, TG and LDL), to inhibit HMGCoA reductase activity, to block lipid peroxidation, to reduce the NO level, and to increase antioxidative enzyme activities. In other words, the RVS glycoprotein had therapeutic properties for treating hypercholesterolemia and hyperlipidemia by inhibiting the activities of HMG-CoA reductase. The RVS glycoprotein in the hyperlipidemic system resulted also blocked lipid peroxidation and increased NO level by enhancing the detoxificating enzyme activities. As a naturally occurring antioxidant, the RVS glycoprotein was effective in lowering plasma cholesterol and altering part of the antioxidative status. Further studies are required to elucidate the precise mechanism for the inhibitory effect of the RVS glycoprotein on cholesterol biosynthesis at the molecular and cellular levels.
